scholarly journals Improving Care for Rare Diseases: A Methodological Guideline to Develop Effective Clinical Guidelines

2014 ◽  
Vol 95 (10) ◽  
pp. e96
Author(s):  
Cynthia Gagnon ◽  
Annie Plourde
2021 ◽  
Vol 12 ◽  
Author(s):  
Pierre Etienne Chazal ◽  
Ségolène Aymé

A timely diagnosis is a critical step to ensure a proper access to expert clinical management for patients. However, diagnosing rare diseases (RD) is a major challenge, as they are not only numerous but also extremely diverse in their expression and cause. This generates a long lag time between first symptoms and diagnosis, unanimously thought to be unacceptably long in many cases, and amenable to improvement. Digital technologies offer new opportunities for improving diagnosis and care in a sector with urgent needs. However, developing and testing digital solutions would only be possible for a limited number of rare diseases (RD). The approach presented here aims at proposing an objective way of defining a subset of “priority” RD to focus on for the development and test of new solutions to reduce the time to diagnosis. An approach which is relevant not only when developing and testing new digital solutions but also organizational solutions in the field of RDs. The priority RDs presented herein have been highlighted using two objective criteria: the existence of a well-defined and established standard of care management, defined as the availability of a medicinal product specifically targeting the disease; and / or the existence of authoritative clinical guidelines. Our approach, based on French data, led to the establishment of a list of 251 RD for which a delayed diagnosis would be especially detrimental for the patient. This work demonstrates the feasibility of identifying objectively a subset of RD at urgent needs for the development of solutions to reduce the delay to diagnosis, if choices have to be made, based on publicly and well-established available data. The proposed list needs to be updated and adapted to the local situation, and validated by experts to establish if the delay to diagnosis can be reduced.


2012 ◽  
Vol 7 (Suppl 2) ◽  
pp. A12 ◽  
Author(s):  
Odile Kremp ◽  
Patrice Dosquet ◽  
Ana Rath

2020 ◽  
Author(s):  
Pierre-Etienne CHAZAL ◽  
Anne-Sophie CHALANDON ◽  
Ségolène AYMÉ ◽  
Christian DELEUZE

Abstract BackgroundA timely diagnosis is a critical step to ensure a proper access to expert clinical management for patients. However, diagnosing rare diseases (RD) is a major challenge, as these diseases are extremely diverse in their expression, cause, semiology and nosology. Today, the development of digital technologies offers genuine opportunities for improving diagnosis and care in a sector with urgent needs. However, developing and testing digital solutions would only be possible for a limited number of Rare Diseases (RD). ResultsThe approach presented in this article aims at proposing an ethical and rational way of defining a subset of “priority” rare diseases to focus on, based on pathologies for which an established and effective standard of care management is defined. Two types of management were considered: the existence of a medicinal product specifically targeting the disease; and / or the existence of authoritative clinical guidelines in France. Our work led to the establishment of a list of 251 RD for which a delayed diagnosis would be especially detrimental. ConclusionIt remains now to establish whether the diagnosis of these RD is especially delayed, or not, before setting up targeted initiatives to reverse the situation. Clarifying choices when taking initiatives to develop solution in a field with so many unmet needs is an element of an ethical approach.


2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.


2004 ◽  
Author(s):  
R. M. A. van Nispen ◽  
P. M. Rijken ◽  
M. J. W. M. Heijmans

2012 ◽  
Author(s):  
Consuelo Gonzalez-Suarez ◽  
Karen Grimmer-Somers ◽  
Janine Dizon ◽  
Ellena King ◽  
Sylvan Lorenzo ◽  
...  

2018 ◽  
Author(s):  
Angela Abicht ◽  
Teresa Neuhann ◽  
Stefanie Balg ◽  
Daniela Gonzalez-Fassreiner ◽  
Verena Steinke-Lange ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document